FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer-Reference-Cited by-同舟云学术

FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer

Published:2022-02 Issue: Volume:526 Page:217-224
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Chiodelli Paola,Coltrini Daniela,Turati Marta,Cerasuolo Marianna,Maccarinelli Federica^ORCID,Rezzola Sara,Grillo Elisabetta^ORCID,Giacomini Arianna,Taranto Sara^ORCID,Mussi Silvia,Ligresti Alessia^ORCID,Presta Marco^ORCID,Ronca Roberto^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Cancer statistics, 2016;Siegel;CA A Cancer J. Clin.,2016

2. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours;Humphrey;Eur. Urol.,2016

3. New therapies for castration-resistant prostate cancer: efficacy and safety;Beltran;Eur. Urol.,2011

4. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development;Hsieh;Lancet Oncol.,2007

5. The development of androgen-independent prostate cancer;Feldman;Nat. Rev. Cancer,2001

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

2. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

3. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer;Cancer Letters;2024-06

4. Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies;International Journal of Cancer;2024-04-11

5. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions;Nature Reviews Clinical Oncology;2024-02-29